<DOC>
	<DOCNO>NCT02817451</DOCNO>
	<brief_summary>Study ass confirm adequate immunogenicity safety profile Sanofi Pasteur 's DTaP-Hep B-IPV-PRP-T fully liquid combine hexavalent vaccine administer HIV-exposed uninfected infant ( HIV-exposed uninfected ) HIV-exposed infected infant ( HIV-exposed infect ) . Primary Objectives : - To evaluate immunogenicity study vaccine 1 month 3-dose primary series HIV-exposed infected HIV-exposed uninfected infant . - To describe persistence antibody receipt booster vaccination HIV-exposed infected HIV-exposed uninfected infant . - To evaluate immunogenicity study vaccine 1 month booster dose HIV-exposed infected HIV-exposed uninfected infant . Secondary Objectives - To describe safety profile dos study vaccine administer 3-dose infant primary series HIV-exposed infected HIV-exposed uninfected infant . - To describe safety profile study vaccine administer booster HIV-exposed infected HIV-exposed uninfected infant .</brief_summary>
	<brief_title>DTaP-IPV-HB-PRP-T Combined Vaccine Primary Series 2nd Year Life Booster HIV-Exposed Infected Uninfected</brief_title>
	<detailed_description>Male female infant bear HIV infected mother test polymerase chain reaction ( PCR ) HIV infection , infect uninfected infant invite approximately 6 week age enroll trial . They enrol 2 group receive primary vaccination Sanofi Pasteur 's DTaP-IPV-HB-PRP-T combine vaccine 6 , 10 14 week age booster dose approximately 15 18 month age receive booster dose Sanofi Pasteur 's DTaP-IPV-HB-PRP-T combine vaccine .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>( Screening Criteria ) At least 18 year age time subject 's PCR blood sample draw Documented proof HIV infection mother Born adult mother age 35 49 day ( 5 7 week age ) day inclusion Group A subject must HIV infect , document result PCR test , follow antiretroviral therapy accord national recommendation ; Group B subject must HIV expose uninfected infant , document result PCR test . Born birth weight ≥ 2.5 kg Informed consent form sign parent ( ) /legal guardian ( ) one independent witness parent ( ) /legal guardian ( ) illiterate Subject parent ( ) /legal guardian ( ) able attend schedule visit comply trial procedure . Participation another clinical trial investigational product 4 week precede trial inclusion ( receipt study vaccine ) plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Group A subject diagnose chronic condition , except HIV infection , experience blood bloodderived product receive experience thrombocytopenia bleed disorder ; Group B subject diagnose chronic illness experience blood bloodderived product receive experience thrombocytopenia bleed disorder . Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis ( oral polio vaccine [ OPV ] give birth constitute exclusion criterion ) , hepatitis B ( birth dose Hep B vaccine constitute exclusion criterion ) diseases Hib infection trial vaccine another vaccine . Previous vaccination Bacillus CalmetteGuerin ( BCG ) consider exclusion criterion History diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B , Haemophilus influenzae type b infection ( confirm either clinically , serologically microbiologically ) History seizure history uncontrolled neurologic disorder uncontrolled epilepsy treatment condition establish , condition stabilize benefit clearly outweigh risk Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine ( ) use trial vaccine contain substance Febrile ( axillary temperature ≥ 37.4°C ) acute illness day inclusion ( temporary contraindication ) .</criteria>
	<gender>All</gender>
	<minimum_age>5 Weeks</minimum_age>
	<maximum_age>7 Weeks</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>DTaP IPV HB PRP-T Combined Vaccine</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
</DOC>